NASDAQ:ZURA Zura Bio Q1 2025 Earnings Report $4.14 -0.02 (-0.48%) Closing price 04:00 PM EasternExtended Trading$4.23 +0.09 (+2.15%) As of 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Zura Bio EPS ResultsActual EPS-$0.19Consensus EPS -$0.17Beat/MissMissed by -$0.02One Year Ago EPSN/AZura Bio Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AZura Bio Announcement DetailsQuarterQ1 2025Date5/8/2025TimeBefore Market OpensConference Call DateThursday, May 8, 2025Conference Call Time7:00AM ETUpcoming EarningsZura Bio's Q3 2026 earnings is estimated for Thursday, November 12, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 13, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Zura Bio Earnings HeadlinesZura Bio Limited (ZURA) Latest Press Releases & Corporate News - Yahoo FinanceSeptember 17, 2026 | finance.yahoo.comZura Bio (ZURA) Hits Enrollment Milestones As Losses Widen SharplySeptember 11, 2026 | finance.yahoo.comLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.October 1 at 1:00 AM | InvestorPlace (Ad)Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 21, 2026 | businesswire.comZura Bio Reports Second Quarter 2026 Financial Results and Recent Corporate UpdatesAugust 11, 2026 | businesswire.comZura Bio Stock (NASDAQ:ZURAW), Analyst Ratings, Price Targets, PredictionsJuly 27, 2026 | benzinga.comSee More Zura Bio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Zura Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Zura Bio and other key companies, straight to your email. Email Address About Zura BioZura Bio (NASDAQ:ZURA) (NASDAQ: ZURA) is a clinical-stage biotechnology company focused on developing medicines for chronic inflammatory and immune-mediated diseases. The company is advancing therapies designed to address conditions with significant unmet medical needs, including hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis and inflammatory bowel disease. Zura Bio’s pipeline includes ZB-106, an investigational inhibitor of interleukin-17A and interleukin-17F being evaluated in inflammatory diseases, and ZB-880, an investigational therapy targeting TL1A, a cytokine associated with intestinal inflammation. These candidates are being studied through clinical development programs rather than marketed as approved products. The company was formed in 2022 and became a publicly traded business in 2023 through a business combination with JATT Acquisition Corp. Zura Bio conducts development activities and clinical research through international programs. As a clinical-stage company, its operations are centered on research, clinical trials and regulatory preparation, with no commercial product portfolio described here.View Zura Bio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Micron’s Earnings Reveal Why the AI Memory Boom May Last LongerAnthropic's IPO Could Put Amazon's and Alphabet's Paper Profits to the TestBoeing’s Fighter Victory Opens the Door to Decades of Defense RevenueCleared for Takeoff: AAR Corp. Expands Its Aerospace Aftermarket ReachJabil’s Double-Beat and Raise Is a Signal That This Rally Will ContinueMicrosoft's AI Spending Didn't Change—Wall Street's View of It DidL3Harris’ $6 Billion THAAD Win Comes at a Crucial Moment for the Stock Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
